DOP2018000293A - Moduladores de moléculas pequeñas de pantothenate kinases - Google Patents
Moduladores de moléculas pequeñas de pantothenate kinasesInfo
- Publication number
- DOP2018000293A DOP2018000293A DO2018000293A DO2018000293A DOP2018000293A DO P2018000293 A DOP2018000293 A DO P2018000293A DO 2018000293 A DO2018000293 A DO 2018000293A DO 2018000293 A DO2018000293 A DO 2018000293A DO P2018000293 A DOP2018000293 A DO P2018000293A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- modulators
- small molecules
- pantothenate kinases
- pantothenate
- kinases
- Prior art date
Links
- 108010021592 Pantothenate kinase Proteins 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354012P | 2016-06-23 | 2016-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2018000293A true DOP2018000293A (es) | 2019-04-15 |
Family
ID=60783428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2018000293A DOP2018000293A (es) | 2016-06-23 | 2018-12-21 | Moduladores de moléculas pequeñas de pantothenate kinases |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10899734B2 (enExample) |
| EP (1) | EP3474667A4 (enExample) |
| JP (1) | JP7078555B2 (enExample) |
| KR (1) | KR102459256B1 (enExample) |
| CN (1) | CN109561680B (enExample) |
| AU (1) | AU2017281907B2 (enExample) |
| CA (1) | CA3025260A1 (enExample) |
| DO (1) | DOP2018000293A (enExample) |
| IL (1) | IL263649B (enExample) |
| MX (1) | MX383697B (enExample) |
| SA (1) | SA518400696B1 (enExample) |
| SG (1) | SG11201811023UA (enExample) |
| WO (1) | WO2017223474A1 (enExample) |
| ZA (1) | ZA201808099B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383697B (es) | 2016-06-23 | 2025-03-14 | St Jude Childrens Res Hospital Inc | Moduladores de moleculas peque?as de pantotenato cinasas |
| KR102728619B1 (ko) * | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| CA3086711A1 (en) * | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Use of arylpiperazine-1-carboxamide derivatives in the treatment of coenzyme a-mediated disorders |
| JPWO2020017569A1 (ja) * | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| EP3946312A4 (en) * | 2019-03-27 | 2023-04-19 | St. Jude Children's Research Hospital | SMALL MOLECULE MODULATORS OF PANK |
| WO2020203609A1 (ja) * | 2019-03-29 | 2020-10-08 | 日本ケミファ株式会社 | 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| EP4262814A4 (en) * | 2020-12-16 | 2025-02-26 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| TW202417421A (zh) * | 2022-08-08 | 2024-05-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之雜環醯胺及脲化合物 |
| CN119745886A (zh) * | 2025-01-20 | 2025-04-04 | 中国药科大学 | 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| EP1322628A2 (en) * | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| JP4831577B2 (ja) * | 2003-07-30 | 2011-12-07 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリダジン誘導体および治療剤としての用途 |
| US20060035884A1 (en) | 2004-05-20 | 2006-02-16 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| CA2668811A1 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| CA2690378A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CN103619825B (zh) | 2011-07-01 | 2015-10-14 | 瑞敏德股份有限公司 | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 |
| CA2873097A1 (en) | 2012-05-11 | 2013-11-14 | Todd M. Hansen | Pyridazine and pyridine derivatives as nampt inhibitors |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| CN107922377A (zh) | 2015-04-17 | 2018-04-17 | 美国印第安纳大学研究和技术公司 | 乙肝病毒组装效应子 |
| MX383697B (es) | 2016-06-23 | 2025-03-14 | St Jude Childrens Res Hospital Inc | Moduladores de moleculas peque?as de pantotenato cinasas |
-
2017
- 2017-06-23 MX MX2018015170A patent/MX383697B/es unknown
- 2017-06-23 EP EP17816310.1A patent/EP3474667A4/en active Pending
- 2017-06-23 CA CA3025260A patent/CA3025260A1/en active Pending
- 2017-06-23 US US16/307,473 patent/US10899734B2/en active Active
- 2017-06-23 WO PCT/US2017/039037 patent/WO2017223474A1/en not_active Ceased
- 2017-06-23 CN CN201780043423.3A patent/CN109561680B/zh active Active
- 2017-06-23 KR KR1020197000671A patent/KR102459256B1/ko active Active
- 2017-06-23 SG SG11201811023UA patent/SG11201811023UA/en unknown
- 2017-06-23 JP JP2018566834A patent/JP7078555B2/ja active Active
- 2017-06-23 AU AU2017281907A patent/AU2017281907B2/en active Active
-
2018
- 2018-11-29 ZA ZA2018/08099A patent/ZA201808099B/en unknown
- 2018-12-11 IL IL263649A patent/IL263649B/en unknown
- 2018-12-19 SA SA518400696A patent/SA518400696B1/ar unknown
- 2018-12-21 DO DO2018000293A patent/DOP2018000293A/es unknown
-
2020
- 2020-12-14 US US17/120,800 patent/US20210246113A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3474667A1 (en) | 2019-05-01 |
| IL263649A (en) | 2019-01-31 |
| RU2019101613A3 (enExample) | 2020-12-03 |
| NZ749147A (en) | 2024-04-26 |
| RU2019101613A (ru) | 2020-07-23 |
| IL263649B (en) | 2022-04-01 |
| CA3025260A1 (en) | 2017-12-28 |
| AU2017281907A1 (en) | 2019-01-03 |
| KR20190022620A (ko) | 2019-03-06 |
| MX383697B (es) | 2025-03-14 |
| SG11201811023UA (en) | 2019-01-30 |
| AU2017281907B2 (en) | 2021-10-21 |
| JP2019518764A (ja) | 2019-07-04 |
| ZA201808099B (en) | 2019-07-31 |
| CN109561680B (zh) | 2021-07-13 |
| JP7078555B2 (ja) | 2022-05-31 |
| US20210246113A1 (en) | 2021-08-12 |
| EP3474667A4 (en) | 2019-11-27 |
| BR112018076441A2 (pt) | 2019-04-09 |
| SA518400696B1 (ar) | 2023-01-09 |
| US10899734B2 (en) | 2021-01-26 |
| US20190300499A1 (en) | 2019-10-03 |
| KR102459256B1 (ko) | 2022-10-25 |
| CN109561680A (zh) | 2019-04-02 |
| WO2017223474A1 (en) | 2017-12-28 |
| MX2018015170A (es) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1013I1 (fr) | Macrocycles de diaryle en tant que modulateurs de protéines kinases | |
| DOP2018000293A (es) | Moduladores de moléculas pequeñas de pantothenate kinases | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| EP3631917A4 (en) | FIBER-BASED OPTICAL MODULATOR | |
| MA55328A (fr) | Modulateurs de ror-gamma | |
| EP3619310A4 (en) | Modulatory polynucleotides | |
| MA53943A (fr) | Modulateurs de ror-gamma | |
| PL3507418T3 (pl) | Sposoby biopochodnej derywatyzacji powierzchni celulozowych | |
| EP3317285A4 (en) | CHIRAL DIARYL MACROCLES AS MODULATORS OF PROTEIN KINASES | |
| EP3419667A4 (en) | MULTISPECIFIC MOLECULES | |
| PL3160498T3 (pl) | Cząsteczki na bazie IL-15 i sposoby ich zastosowania | |
| EP3383386A4 (en) | MODULATORS OF CHEMOKIN RECEPTORS | |
| HUE042443T2 (hu) | GPR6 tetrahidropiridopirazin-modulátorai | |
| EP3333619A4 (en) | OPTICAL MODULATOR | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| IL275658A (en) | Small molecule modulators of pantothenate kinases | |
| PL3311169T3 (pl) | Oznaczenie do identyfikacji modulatorów | |
| DK3242685T3 (da) | Cxcr4-bindende molekyler | |
| LT3685847T (lt) | Komplemento aktyvumo moduliatoriai | |
| EP3563296A4 (en) | ZERO SHOT LEARNING USING A MULTI-SCALE MANIFOLD ALIGNMENT | |
| HUE056613T2 (hu) | Komplementaktivitás modulátorai | |
| EP3408815A4 (en) | VALIDATION OF TRANSACTIONS | |
| EP3532062A4 (en) | ROR GAMMA MODULATORS | |
| EP3384840A4 (en) | INSTRUMENT | |
| EP3477362A4 (en) | ELECTROOPTICAL MODULATOR |